Bristol-Myers Squibb reports positive gastric cancer data for Opdivo

Bristol-Myers Squibb has announced new clinical trial data showing the effectiveness of its drug Opdivo in the treatment of advanced forms of gastric cancer.

Data from the phase III trial ONO-4538-12 showed that Opdivo significantly reduced by 37 percent the risk of death in patients with previously treated advanced gastric cancer that has proven refractory to or intolerant of standard therapy.

This condition does not have a current standard-of-care treatment approach, but Opdivo was shown to be associated with 12-month overall survival rates of 26.6 percent, compared to only 10.9 percent in placebo-treated patients.

ONO-4538-12 represents the first phase III immuno-oncology trial to demonstrate improved survival for patients with previously treated advanced or recurrent gastric cancer, meaning Opdivo could offer a promising new therapeutic option for these patients.

Dr Ian Waxman, development lead for gastrointestinal oncology at Bristol-Myers Squibb, said: "We find these results with Opdivo encouraging, as gastric cancer is a leading cause of cancer death globally and unmet needs remain for patients with advanced forms of this disease."

To date, the Opdivo clinical development programme has enrolled more than 25,000 patients, spanning a range of cancer types.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.